What Researchers Did
Researchers conducted a randomized controlled trial in China assigning 80 patients with chronic insomnia at high altitude to either 10 days of hyperbaric oxygen treatment or standard care, measuring sleep quality, fatigue, anxiety, and depression.
What They Found
The HBOT group showed significantly better sleep quality scores after treatment compared to the control group (PSQI score: 4.6 vs. 9.1; p < 0.0001). The Insomnia Severity Index was also significantly lower in the HBOT group (5.0 vs. 9.8; p < 0.0001). The HBOT group also reported improvements in fatigue, anxiety, and depression. No serious side effects were reported in either group.
What This Means for Canadian Patients
While this study was conducted at high altitude, a specific physiological context less common in most of Canada, the results suggest HBOT can meaningfully improve sleep in patients where low oxygen availability contributes to insomnia. Canadians in high-altitude regions or those with oxygen-related sleep disturbances may benefit from exploring this treatment.
Canadian Relevance
No direct Canadian connection identified. Chronic insomnia is not an OHIP-covered indication for HBOT.
Study Limitations
The open-label design means patients knew which treatment they received, introducing potential placebo bias; also, high-altitude insomnia may not respond the same as sea-level insomnia.